AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ETODOLAC

10 registrations across 5 African markets— 7 active

Markets with ETODOLAC

Recent registrations

Brand / ProductMarketHolderStatusExpires
ETOVA-400 400MG COMPRIME PELLICULE BOITE DE 10🇨🇮Côte d'IvoireIPCA LABORATORIES LIMITEDactiveMar 2028
ETOVA-400
TABLET, COATED; ORAL
🇿🇼ZimbabweIPCA LABORATORIES LTDactiveDec 2027
SETOLAC ER 300MG COMPRIME BOITE DE 10🇨🇮Côte d'IvoireZUVENTUS HEALTHCAREexpiredFeb 2024
LODINE TABLETS 300 mg*🇿🇦South AfricaAKROMED PRODUCTS (PTY) LTDsuspendedJan 2024
LODINE TABLETS 200 mg*🇿🇦South AfricaAKROMED PRODUCTS (PTY) LTDsuspendedJan 2024
LODINE CAPSULES 300 mg*🇿🇦South AfricaAKROMED PRODUCTS (PTY) LTDactiveJan 1900
LODINE
comprimé / 300 mg
🇸🇳SenegalWYETH FRANCEactive
Proxym-300
Tablet, Film-coated
🇹🇿TanzaniaEmcure Pharmaceuticals Ltdactive
Etova - 400
Tablets
🇹🇿TanzaniaIPCA Laboratories Limitedactive
LODINE
comprimé pelliculé / 300mg
🇸🇳SenegalDEXOactive

ETODOLAC in Africa — Regulatory Overview

ETODOLAC is registered across 5 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Côte d'Ivoire, Senegal, Tanzania and 1 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 7 (70%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.